Dose response to budesonide using adenosine monophosphate (AMP) bronchial challenge: assessment of two dry powder inhalers Source: Eur Respir J 2002; 20: Suppl. 38, 502s Year: 2002
Effects of histamine and leukotriene antagonism on mannitol and adenosine monophosphate (AMP) challenge Source: Eur Respir J 2002; 20: Suppl. 38, 386s Year: 2002
Dose-related effects of formoterol on airway responsiveness to adenosine 5'-monophosphate and histamine Source: Eur Respir J 2002; 19: 611-616 Year: 2002
PBF-680, an oral A1 adenosine receptor antagonist, inhibits adenosine monophosphate (AMP) airway hyperresponsiveness (AHR) in mild-to-moderate asthma: a Phase-IIa proof-of-concept trial Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights Year: 2020
Adenosine 5' – triphosphate (ATP) and adenosine 5' – monophosphate (AMP) challenge testing in healthy non-smokers and patients with mild asthma Source: Eur Respir J 2003; 22: Suppl. 45, 350s Year: 2003
Effects of salbutamol on gas exchange abnormalities and sputum neutrophilia induced by adenosine 5‘-monophosphate (AMP) in mild asthma Source: Eur Respir J 2006; 28: Suppl. 50, 669s Year: 2006
Association between atopic status and airway reactivity to methacholine and adenosine monophosphate Source: Eur Respir J 2001; 18: Suppl. 33, 102s Year: 2001
Cellular and gas exchange responses to adenosine 5‘-monophosphate (AMP) challenge in mild asthma Source: Eur Respir J 2004; 24: Suppl. 48, 442s Year: 2004
Direct and indirect bronchial challenge tests with Methacholine and Adenosine monophosphate in asthmatic patients and healthy subjects Source: Annual Congress 2010 - Advances in lung function II Year: 2010
Bronchoconstriction induced by inhaled adenosine 5'-monophosphate in subjects with allergic rhinitis Source: Eur Respir J 2001; 17: 64-70 Year: 2001
Airway hyperresponsiveness accessed by adenosine monophosphate bronchial provocation test Source: Annual Congress 2009 - Airway hyperresponsiveness: mechanism and assessment Year: 2009
The adenosine A2A -Receptor is not involved in adenosine induced bronchoconstriction in asthmatics Source: Eur Respir J 2003; 22: Suppl. 45, 103s Year: 2003
Adenosine 5’ – triphosphate (ATP) and adenosine 5' – monophosphate (AMP) challenge testing in current smokers and patients with chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2003; 22: Suppl. 45, 414s Year: 2003
The bronchoprotective effects of levocetirizine on adenosine monophosphate challenge in patients with atopic asthma Source: Eur Respir J 2004; 24: Suppl. 48, 220s Year: 2004
Protective effect of budesonide/formoterol in a model of repeated exposure to inhaled adenosine 5‘-monophosphate (AMP) in patients with asthma Source: Eur Respir J 2007; 30: Suppl. 51, 353s Year: 2007
Ciclesonide decreases exhaled breath nitric oxide and rapidly reduces airway responsiveness to adenosine monophosphate in asthma patients Source: Eur Respir J 2005; 26: Suppl. 49, 252s Year: 2005
Effect of adenosine 5´-triphosphate (ATP) challenge vs. adenosine 5´-monophosphate (AMP) on the threshold of capsaicin-induced cough in healthy non-smokers, current smokers and patients with asthma Source: Eur Respir J 2004; 24: Suppl. 48, 708s Year: 2004
Airway responsiveness to methacholine (Mch), adenosine 5- monophosphate (AMP), mannitol (Man), eucapnic voluntary hyperpnea (EVH) and a sport-specific field exercise challenge (Ex) in cross country ski athletes Source: Eur Respir J 2002; 20: Suppl. 38, 410s Year: 2002
Effect of budesonide on AMP and methacholine airway responsiveness and sputum cellularity: a time-course study Source: Eur Respir J 2001; 18: Suppl. 33, 163s Year: 2001
Unraveling adenosine and AMP induced dyspnea sensation in asthma Source: International Congress 2018 – Tests and trends in asthma Year: 2018